Interpreting a Discordant Susceptibility Result and Selecting Therapy
A 70-year-old man with a chronic indwelling urinary catheter and recurrent UTIs has a urine culture growing Klebsiella pneumoniae at >100,000 CFU/mL. The automated susceptibility panel reports: ampicillin R, ampicillin-sulbactam R, ceftriaxone R, cefepime S, meropenem S, ertapenem S, gentamicin S, ciprofloxacin R, TMP-SMX R. He is asymptomatic except for cloudy urine and has no fever or flank pain. He has a history of an ESBL-producing E. coli UTI 1 year ago. The laboratory reports the isolate as an ESBL producer by phenotypic confirmatory testing but notes that cefepime tests susceptible.
1. How do you interpret the discordance between ESBL production and cefepime susceptibility, and what does it mean for therapy?
Read the worked answer
Phenotypic ESBL production with a susceptible cefepime result creates a discordance. Some ESBL enzymes (e.g., certain CTX-M variants) hydrolyze ceftriaxone more than cefepime, and cefepime may test susceptible in vitro; however, clinical outcome data for cefepime in ESBL infections are mixed, and the 'susceptible' result may not translate to reliable efficacy, particularly at standard doses. The safer interpretation is to treat the isolate as ESBL-producing and avoid ceftriaxone and cefepime unless a high-dose prolonged-infusion strategy is used and the patient is stable. Carbapenems (meropenem, ertapenem) remain the most reliable options for invasive ESBL infections. For a urinary source, ertapenem is reasonable if the organism is susceptible, though it lacks Pseudomonas coverage (not relevant here).
2. Does this patient need antibiotics at all? Justify your answer.
Read the worked answer
No-this is asymptomatic bacteriuria (cloudy urine alone is not a symptom). Guidelines recommend against treating asymptomatic bacteriuria in most patients, including those with indwelling catheters, because treatment does not improve outcomes and promotes resistance and C. difficile. The exception would be pregnancy or before urologic procedures with mucosal trauma. I would not treat; instead, I would address the catheter (consider removal or exchange if malfunctioning) and monitor for symptoms. Documenting the rationale is important for antimicrobial stewardship.
3. If she develops symptoms and treatment is indicated, what regimen and duration would you choose, and what follow-up would you recommend?
Read the worked answer
If symptomatic (fever, flank pain, dysuria, or systemic signs), I would treat as complicated UTI. Given ESBL production and prior ESBL history, I would choose a carbapenem (ertapenem if no Pseudomonas concern, or meropenem) based on susceptibility, avoiding cefepime and fluoroquinolones (resistant). Duration: 7 days for complicated UTI with prompt response, or 14 days for pyelonephritis. I would obtain a repeat culture only if symptoms persist or recur, remove or exchange the catheter if possible, and consider infectious diseases consultation. I would also review prior ESBL history to guide empiric therapy if she deteriorates.